| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.965 AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9532 to 0.9759 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C14; group 'BRCA'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.891 Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.8654 to 0.9159 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E14; group 'BRCA'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.819 Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.7855 to 0.8525 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D14; group 'BRCA'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.95 AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9366 to 0.9639 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C24; group 'CHOL'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.772 Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.7133 to 0.8300 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E24; group 'CHOL'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.673 Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.6075 to 0.7391 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D24; group 'CHOL'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.966 AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9556 to 0.9769 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C34; group 'CRC'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.872 Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.8325 to 0.9108 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E34; group 'CRC'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.793 Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.7427 to 0.8440 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D34; group 'CRC'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2) Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024) | 0.937 AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9260 to 0.9488 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Jiang cohort liver cancer cross-validation ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C84; group 'LIHC'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.971 AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9486 to 0.9925 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C54; group 'NSCLC'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.91 Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.8574 to 0.9626 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E54; group 'NSCLC'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.825 Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.7538 to 0.8962 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D54; group 'NSCLC'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.987 AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9812 to 0.9932 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C64; group 'OV'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.94 Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.9082 to 0.9718. Closing bracket missing in the printed cell. Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E64; group 'OV'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.89 Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.8481 to 0.9319 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D64; group 'OV'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.82 AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.7884 to 0.8517 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C74; group 'PAAD'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.616 Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.5621 to 0.6696 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E74; group 'PAAD'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.523 Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.4668 to 0.5798 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D74; group 'PAAD'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.958 AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9528 to 0.9631 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C4; group 'PANCAN'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.962 AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation) unitless · higher Uncertainty: 95% CI 0.9446 to 0.9803 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C44; group 'STAD'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.937 Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.9098 to 0.9635 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E44; group 'STAD'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.837 Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation) fraction · higher Uncertainty: 95% CI 0.7938 to 0.8795 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D44; group 'STAD'; row 'PFE'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3) Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.706 AUROC (lung cancer vs non-cancer; independent validation) unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C14; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'PFE'; column 'AUC' |
|---|
| Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3) Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.45 Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation) fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcePFE (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E14; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'PFE'; column 'Sensitivity @85% specificity' |
|---|